Firazyr advisory committee canceled
Executive Summary
Jerini's hereditary angiodema treatment Firazyr (icatibant) will not undergo a review by FDA's Pulmonary-Allergy Drugs Advisory Committee, the firm says Jan. 8. The panel was scheduled to meet Feb. 20 to discuss the orphan drug candidate, which has an April 26 user fee date under priority review...